Cellular Biomedicine Group Inc. (CBMG) Earns Buy Rating from Analysts at Maxim Group

Maxim Group assumed coverage on shares of Cellular Biomedicine Group Inc. (NASDAQ:CBMG) in a research report sent to investors on Thursday morning. The firm issued a buy rating and a $16.00 target price on the stock.

Shares of Cellular Biomedicine Group (NASDAQ:CBMG) opened at 14.38 on Thursday. The company’s market capitalization is $202.79 million. Cellular Biomedicine Group has a 52 week low of $10.44 and a 52 week high of $25.20. The firm has a 50 day moving average price of $14.15 and a 200 day moving average price of $15.33.

Cellular Biomedicine Group Company Profile

Cellular Biomedicine Group, Inc (CBMG) is a biomedicine company. The Company is engaged in the development of treatments for cancerous and degenerative diseases utilizing cell-based technologies. The Company operates in Biomedicine Cell Therapy segment. The Company’s technology includes platforms, such as Immune Cell therapy for treatment of broad range of cancers using Vaccine, T Cells Receptor (TCR) clonality analysis technology and T Central Memory Cell (Tcm) preparation methodologies, Chimeric Antigen Receptor T cell (CAR-T), and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases, with primary research and manufacturing facilities in China.

5 Day Chart for NASDAQ:CBMG

Receive News & Ratings for Cellular Biomedicine Group Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellular Biomedicine Group Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

© 2006-2016 Mideast Time.